bioRxivMolecular BiologyPreprint
Identification of C270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease
Hangchen HuiD, Qian WangiD, Haixia SuiD, Qiang ShaoiD, Wenfeng ZhaoiD, Guofeng CheniD, Minjun LiiD, Yechun Xu
Abstract
The papain-like protease (PLpro) in coronavirus is one of key cysteine proteases responsible for the proteolytic processing of viral polyproteins, and plays an important role in dysregulation of host immune response. PLpro is a promising therapeutic target with a major challenge in inhibitor design due to the restricted S1/S2 sites for two consecutive glycine of substrates. Here we reported the discovery of two activators of the SARS-CoV-2 PLpro from a biochemical screening, and the identification of the unique residue, C270, as an allosteric and covalent regulation site for the activators. This site was also specifically modified by glutathione oxidized, resulting in the S-glutathionylation and activation of the protease. Furthermore, one compound was found to allosterically inhibit the protease by covalent binding to this crucial site. Together, these results elucidated an unrevealed molecular mechanism for allosteric modulation of the proteases activity, and provided a new strategy for discovery of allosteric inhibitors of the SARS-CoV-2 PLpro.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of Novel Allosteric Sites of SARS-CoV-2 Papain-Like Protease (PLpro) for the Development of COVID-19 Antivirals
J. C. Ferreira, K. Al Adem, … W. M. Rabeh·bioRxiv·May 16, 2023
- SARS-CoV-2 papain-like protease PLpro in complex with natural compounds reveal allosteric sites for antiviral drug design
V. Srinivasan, H. Brognaro, … P·Communications BiologyPeer-reviewed·Aug 11, 2022
- Mechanism and inhibition of SARS-CoV-2 PLpro
T. Klemm, G. Ebert, … D. Komander·bioRxiv·Jun 18, 2020
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
J. Osipiuk, Saara‐Anne Azizi, … A. Joachimiak·Nature CommunicationsPeer-reviewed·Feb 2, 2021
- Drug Repurposing for the SARS-CoV-2 Papain-Like Protease
C.-C. D. Cho, S. G. Li, … W. R. Liu·bioRxiv·Jun 4, 2021
- Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules